IFRX
Price
$1.18Alerts
Change
-$0.03 (-2.48%)
Updated
Nov 11 closing price
Capitalization
192.32M
133 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$13.13Alerts
Change
-$0.02 (-0.15%)
Updated
Nov 11 closing price
Capitalization
2.07B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IFRX vs VIR

IFRX vs VIR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IFRX vs. VIR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a Hold and VIR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IFRX with price predictions
Nov 11, 2026

IFRX's Indicator enters downward trend

The Aroon Indicator for IFRX entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator formed such a pattern. In 186 of the 210 cases the stock moved lower. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IFRX as a result. In 88 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for IFRX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.316) is normal, around the industry mean (3.498). P/E Ratio (-2.610) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. IFRX's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. IFRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for VIR with price predictions
Nov 11, 2026

VIR in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026

The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 69 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.

VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 130 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
IFRX vs VIR: Fundamental Ratings
IFRX
VIR
OUTLOOK RATING
1..100
5527
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
8335
P/E GROWTH RATING
1..100
1581
SEASONALITY SCORE
1..100
44n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IFRX's Valuation (2) in the Biotechnology industry is in the same range as VIR (19) in the null industry. This means that IFRX’s stock grew similarly to VIR’s over the last 12 months.

IFRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that IFRX’s stock grew similarly to VIR’s over the last 12 months.

VIR's SMR Rating (96) in the null industry is in the same range as IFRX (97) in the Biotechnology industry. This means that VIR’s stock grew similarly to IFRX’s over the last 12 months.

VIR's Price Growth Rating (35) in the null industry is somewhat better than the same rating for IFRX (83) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than IFRX’s over the last 12 months.

IFRX's P/E Growth Rating (15) in the Biotechnology industry is significantly better than the same rating for VIR (81) in the null industry. This means that IFRX’s stock grew significantly faster than VIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IFRXVIR
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (IFRX: $1.18 vs. VIR: $13.13)
Brand notoriety: IFRX and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 68% vs. VIR: 63%
Market capitalization -- IFRX: $192.32M vs. VIR: $2.07B
IFRX [@Biotechnology] is valued at $192.32M. VIR’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 2 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).

  • IFRX’s FA Score: 2 green, 3 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, both IFRX and VIR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).

  • IFRX’s TA Score: 4 bullish, 4 bearish.
  • VIR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VIR is a better buy in the short-term than IFRX.

Price Growth

IFRX (@Biotechnology) experienced а -20.27% price change this week, while VIR (@Biotechnology) price change was +11.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

IFRX is expected to report earnings on Mar 25, 2027.

VIR is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IFRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with KURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
-2.48%
KURA - IFRX
37%
Loosely correlated
+2.11%
VIR - IFRX
36%
Loosely correlated
-0.15%
SGMT - IFRX
34%
Loosely correlated
+4.78%
BEAM - IFRX
34%
Loosely correlated
+2.62%
CRSP - IFRX
33%
Loosely correlated
+1.33%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-0.15%
BEAM - VIR
54%
Loosely correlated
+2.62%
EDIT - VIR
54%
Loosely correlated
-4.99%
SLDB - VIR
53%
Loosely correlated
+6.00%
BNTC - VIR
52%
Loosely correlated
+2.05%
DNLI - VIR
52%
Loosely correlated
-0.60%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
STXX14.382.39
+19.93%
Tradr 2X Long STX Daily ETF (STXX)
TDI44.660.51
+1.16%
Touchstone Dynamic International ETF (TDI)
ZTRE49.83-0.04
-0.08%
F/M 3-Year Investment Grade Corporate Bond ETF (ZTRE)
IYR102.77-0.21
-0.20%
iShares U.S. Real Estate ETF (IYR)
MHF6.33-0.09
-1.40%
Western Asset Municipal High Income Fund